Evolution and neutralization escape of the SARS-CoV-2 BA. 2.86 subvariant
Abstract Omicron BA. 2.86 subvariant differs from Omicron BA. 2 as well as recently
circulating variants by over 30 mutations in the spike protein alone. Here we report on the …
circulating variants by over 30 mutations in the spike protein alone. Here we report on the …
Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of vaccinated
individuals is increasingly common but rarely results in severe disease, likely due to the …
individuals is increasingly common but rarely results in severe disease, likely due to the …
[HTML][HTML] Inference of epidemic dynamics in the COVID-19 era and beyond
The COVID-19 pandemic demonstrated the key role that epidemiology and modelling play
in analysing infectious threats and supporting decision making in real-time. Motivated by the …
in analysing infectious threats and supporting decision making in real-time. Motivated by the …
Monoclonal antibody levels and protection from COVID-19
Multiple monoclonal antibodies have been shown to be effective for both prophylaxis and
therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled …
therapy for SARS-CoV-2 infection. Here we aggregate data from randomized controlled …
Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment
Abstract Anti–SARS-CoV-2 vaccination has saved millions of lives in the past few years. To
maintain a high level of protection, particularly in at-risk populations, booster doses are …
maintain a high level of protection, particularly in at-risk populations, booster doses are …
Omicron COVID-19 immune correlates analysis of a third dose of mRNA-1273 in the COVE trial
Abstract In the phase 3 Coronavirus Efficacy (COVE) trial (NCT04470427), post-dose two
Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be …
Ancestral Spike-specific binding (bAb) and neutralizing (nAb) antibodies were shown to be …
Discovery of highly potent covalent SARS-CoV-2 3CLpro inhibitors bearing 2-sulfoxyl-1, 3, 4-oxadiazole scaffold for combating COVID-19
FM Zhang, T Huang, F Wang, GS Zhang, D Liu… - European Journal of …, 2023 - Elsevier
Abstract The coronavirus disease (COVID-19) pandemic, caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a major public health …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has emerged as a major public health …
Ursodeoxycholic acid does not affect the clinical outcome of SARS‐CoV‐2 infection: A retrospective study of propensity score‐matched cohorts
Background Ursodeoxycholic acid (UDCA) has been recently proposed as a modulator of
angiotensin‐converting enzyme 2 (ACE2) receptor expression, with potential effects on …
angiotensin‐converting enzyme 2 (ACE2) receptor expression, with potential effects on …
[HTML][HTML] Effectiveness of a bivalent mRNA vaccine dose against symptomatic SARS-CoV-2 infection among US Healthcare personnel, September 2022–May 2023
Background Bivalent mRNA vaccines were recommended since September 2022. However,
coverage with a recent vaccine dose has been limited, and there are few robust estimates of …
coverage with a recent vaccine dose has been limited, and there are few robust estimates of …
Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity
M D'Souza, A Keeshan, CA Gravel, MA Langlois… - npj Vaccines, 2024 - nature.com
Obesity is a recognized factor influencing immune function and infectious disease outcomes.
Characterization of the influence of obesity on SARS-CoV-2 humoral vaccine …
Characterization of the influence of obesity on SARS-CoV-2 humoral vaccine …